Ionis Pharmaceuticals Inc（IONS）股票分析IONSIonis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ionis Pharmaceuticals is not a good buy right now due to a current price of $42.93, which is down 46.12% year-to-date, and an RSI of 39.846 indicating oversold conditions. The forward P/E ratio is extremely high at 90.9091, suggesting that the stock is overvalued relative to its earnings potential. Additionally, the company has faced substantial losses, with a net income loss of $114.646 million in Q2 2026. The main risk is the high forward P/E ratio, which could indicate that the stock is not a good investment at this price point.

15 analysts cover IONS: 5 rate it Buy, 8 Hold and 2 Sell. The average price target is 92.67.